Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11782277 | 0.86 | TYK2 (0.46) | ALDH1A1ELANEKDM4EHPGDHSD17B10 | |
| SCHEMBL7625634 | 0.83 | CA12 (0.38) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6113403 | 0.81 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1044586 | 0.81 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL403705 | 0.79 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27923890 | 0.77 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2809402 | 0.77 | CYP3A4 (0.38) | L3MBTL1TDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL27769118 | 0.77 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27996415 | 0.77 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27403344 | 0.77 | CA12 (0.41) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | claimed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | claimed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | claimed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-10676780-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20200120923-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2020-04-23 | — | — | US | disclosed |
| US-20160348151-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160281133-A1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20140227687-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227688-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8324173-B2 | Peptides useful as dual caspase-2/-6 inhibitors and their biological applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-12-04 | — | — | US | disclosed |
| WO-2009083930-A1 | CASPASE-8 INHIBITORS AND USES THEREOF | THERAPTOSIS (FR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009083929-A1 | CASPASE-1 INHIBITORS AND USES THEREOF | THERAPTOSIS (FR) | 2009-07-09 | — | — | WO | disclosed |
| US-20090042805-A1 | Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-02-12 | — | — | US | disclosed |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | THERAPTOSIS SA (FR) | 2008-12-18 | — | — | US | disclosed |
| EP-1817328-A2 | NEW PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-08-15 | — | — | EP | disclosed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006056487-A2 | PEPTIDES USEFUL AS DUAL CASPASE-2/-6 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | disclosed |
| US-3943153-A | BACTERICIDES | MERCK & CO., INC. (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042805-A1 | Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications | CASP6, CASP2, CASP4 | CA12 4200/4885CA1 3500/4885CA2 2502/4885 |
| US-20080311051-A1 | Caspase-2 Inhibitors And Their Biological Applications | CASP1, CASP2, CASP9 | CA12 4601/4885CA1 2682/4885CA2 1881/4885 |
| US-20200120923-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CA12 781/4885CA1 2628/4885CA2 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.